🇺🇸 FDA

Intelligence · Patents

Expiring patents (≤24 months)

Patent cliff watchlist — pharmaceutical patents approaching loss of exclusivity.

Patents
1,230

Quick answer

1,230 pharmaceutical patents in our index expire within the next 24 months. Use year facets below for annual patent-cliff planning linked to company and drug profiles.

  1. US 7345030

    Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals

    Third Military Medical University, Chinese People's Liberation Army, P.R. of China · Granted Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7345175

    Biphenyl derivatives

    Theravance, Inc. · Granted Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7346387

    Methods for improved selectivity in photo-activation and detection of molecular diagnostic agents

    Provectus Devicetech, Inc. · Granted Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7344722

    Cold-adapted influenza virus

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7344829

    Methods for detecting the efficacy of anticancer treatments

    The Board of Regents of the University of Texas System · Granted Tue Mar 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7348335

    Compositions useful as inhibitors of JAK and other protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7348314

    Compositions and methods for inhibiting viral replication

    Alnylam Europe AG · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7347987

    Inhibition of reactive oxygen species and protection of mammalian cells

    The Regents of the University of Oklahoma · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7348153

    Method for identifying and designing immunogenic peptides

    The Board of Regents of the University of Texas System · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7348004

    Immunoglobulin chimeric monomer-dimer hybrids

    Syntonix Pharmaceuticals, Inc. · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7348319

    Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7348359

    Retinoid X receptor modulators

    Ligand Pharmaceuticals Incorporated · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7348330

    1-azabicyclo [2,2,2] octan-3-one derivatives

    APREA AB · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7348429

    Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process

    TEVA Gyógyszergyár Zártkörüen Müködö Részvénytárasaság · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7348324

    Cyclic amine compounds as CCR5 antagonists

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 25 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7351411

    Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7351408

    Glycoconjugates and methods

    The Regents of the University of California · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7351403

    Sunscreen reagents from unsaturated waxes and triglycerides

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7351702

    Caspase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7351435

    Deglycosylated ricin toxin a-chain vaccine

    The United States of America as represented by the Secretary of the Army · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7351542

    Methods of modulating tubulin deacetylase activity

    The Regents of the University of California · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7351791

    Intermediate for preparing glycopeptide derivatives

    Theravance, Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7351827

    Substituted oxetanes, method of making, and method of use thereof

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7351717

    Substituted pyrrolidine and related compounds

    Theravance, Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7351718

    Substituted pyrrolidine and related compounds

    Theravance, Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7351739

    Bioactive compounds and methods of uses thereof

    Regents of the University of Minnesota · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7351830

    Pancratistatin cyclic phosphate prodrugs and phenpanstatin cyclic phosphate prodrugs

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7351707

    Spiroazacyclic compounds as monoamine receptor modulators

    ACADIA Pharmaceuticals Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7351704

    Indazole-carboxamide compounds as 5-HT4 receptor agonists

    Theravance, Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7351691

    Glycopeptide phosphonate derivatives

    Theravance, Inc. · Granted Tue Apr 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7354711

    Methods for inhibiting immunostimulatory DNA associated responses

    The Department of Veterans Affairs, as represented by the Secretary of United States of America · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7355001

    Organic anion transport protein TCH229

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7354909

    Method for rapid generation of mature dendritic cells

    UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7355012

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7355047

    Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7355079

    Thyronamine derivatives and analogs and methods of use thereof

    The Regents of the University of California · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7355018

    Modified IGF1 polypeptides with increased stability and potency

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7354912

    Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity

    The Board of Regents of the University of Texas System · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7355078

    Processes for the preparation of tomoxetine

    Teva Pharmaceutical Fine Chemicals S.R.L. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7354919

    Isoxazole compositions useful as inhibitors of ERK

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7354928

    Small molecule inhibitors targeted at Bcl-2

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7354936

    2-phenylpyran-4-one derivatives

    ALMIRALL, LLC · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7354939

    Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7353829

    Methods and apparatus for multi-photon photo-activation of therapeutic agents

    Provectus Devicetech, Inc. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7354576

    Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7354578

    Method of tumor regression with VEGF inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is a patent cliff?

A patent cliff is when key pharmaceutical patents expire, opening markets to generics or biosimilars. This hub lists USPTO patents with approaching expiration dates.

Are expiration dates estimates?

Expiration dates derive from USPTO PatentsView grant dates and term estimates. Confirm with Orange Book, patent counsel, and USPTO records before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.